Endometriosis is one of the most common gynecological conditions affecting women of reproductive age — estimated to affect approximately 10 percent of women globally and a significant proportion of women presenting with infertility. It is also one of the conditions about which the most anxiety-generating and least clearly explained information circulates in fertility communities.
The question this article addresses — does endometriosis reduce IVF chances? — is one of the most frequently asked questions by women with endometriosis who are considering fertility treatment. And the answer is more nuanced than either a simple yes or a simple no would suggest.
The honest clinical answer is: it depends — on the stage of endometriosis, on whether surgical treatment has been performed, on specific features of the individual presentation, and on the quality of the IVF protocol designed for that patient. Endometriosis does affect IVF outcomes — but not uniformly, not irreversibly, and not in ways that should lead women with this diagnosis to abandon hope of IVF success.
This article explains what endometriosis is, how it affects fertility, what the evidence shows about IVF outcomes in women with endometriosis, what treatment approaches are available, and what a realistic prognosis looks like for women with endometriosis pursuing IVF at Metro IVF.
What Is Endometriosis?
Endometriosis is a chronic inflammatory condition in which tissue similar to the endometrium — the inner lining of the uterus — grows outside the uterus. This ectopic endometrial tissue can implant on the ovaries, the fallopian tubes, the peritoneum lining the pelvic cavity, the bowel, the bladder, and in rare cases locations outside the pelvis.
Like the endometrium inside the uterus, ectopic endometrial tissue responds to the hormonal changes of the menstrual cycle — proliferating under estrogen stimulation, breaking down with each period. But unlike the endometrial lining, which can shed through the cervix, the ectopic tissue has nowhere to go. The monthly bleeding of the ectopic implants irritates the surrounding tissue, triggers inflammatory responses, and over time produces adhesions — bands of scar tissue — that can distort pelvic anatomy, fuse organs together, and impair the function of the fallopian tubes and ovaries.
Endometriosis is classified by stage — from stage one (minimal, scattered implants) to stage four (severe, with extensive adhesions and ovarian cysts called endometriomas) — according to the American Society for Reproductive Medicine (ASRM) classification. This staging reflects the anatomical extent of the disease and the degree of anatomical distortion, though it does not always correlate perfectly with symptom severity or fertility impact.
The most common symptoms of endometriosis include pelvic pain — particularly dysmenorrhoea (painful periods), dyspareunia (pain during intercourse), and chronic pelvic pain — and infertility. A significant proportion of women with endometriosis have no symptoms at all and are diagnosed only during investigation for infertility.
How Endometriosis Affects Fertility
Endometriosis impairs fertility through multiple mechanisms — and understanding each mechanism is important for understanding how IVF addresses some of them while others remain relevant even in a treated cycle.
Mechanism One: Tubal and Pelvic Anatomical Distortion
In moderate to severe endometriosis (stages three and four), peritubal and periovarian adhesions can significantly distort pelvic anatomy. Fallopian tubes may become blocked, kinked, or immobilized. Ovaries may become adherent to the pelvic sidewall or to each other, limiting their mobility and the embryo's access through the tube. Severe anatomical distortion of this kind effectively prevents natural conception and significantly reduces the probability of IUI success.
IVF bypasses the fallopian tubes entirely — eggs are retrieved directly from the ovaries under ultrasound guidance, fertilization occurs in the laboratory, and embryos are transferred directly into the uterus. Tubal anatomical distortion from endometriosis is therefore the most directly addressable cause of endometriosis-related infertility through IVF.
Mechanism Two: Egg Quality Impairment
The inflammatory environment created by endometriosis — characterized by elevated reactive oxygen species, inflammatory cytokines, and prostaglandins in the peritoneal fluid and within the ovarian follicles — directly affects the quality of eggs developing within the ovaries.
Women with endometriosis consistently show higher rates of immature eggs at retrieval, lower fertilization rates, and poorer embryo developmental quality than age-matched women without endometriosis, particularly in women with ovarian endometriomas — endometriotic cysts on the ovaries.
Endometriomas are particularly damaging to the ovarian reserve and egg quality. The cyst fluid of an endometrioma contains iron-rich, oxidative blood byproducts that are directly toxic to the granulosa cells and oocytes surrounding the cyst. Women with endometriomas typically have reduced AMH levels — reflecting the destruction of ovarian tissue by the endometrioma — and produce fewer eggs of lower developmental quality than would be expected for their age without the endometrioma.
This egg quality impairment is the mechanism that most directly reduces IVF success rates in women with endometriosis — and it is the mechanism that is hardest to fully address through treatment.
Mechanism Three: Endometrial Receptivity
Whether endometriosis affects endometrial receptivity — the capacity of the uterine lining to accept and sustain an implanting embryo — has been debated in the reproductive medicine literature for decades. The current evidence suggests that in most women with endometriosis, endometrial receptivity is not significantly impaired, and that the uterus is capable of sustaining a pregnancy when good-quality embryos are transferred.
However, specific features of endometriosis may affect receptivity in some patients. Adenomyosis — a related condition in which endometrial tissue invades the uterine muscle — is frequently associated with endometriosis and is associated with reduced implantation rates and higher miscarriage rates. In women with endometriosis who have unexplained repeated implantation failure, adenomyosis should be considered and assessed.
Mechanism Four: Ovarian Reserve Reduction
Endometriomas directly reduce ovarian reserve — the pool of remaining follicles — through the toxic effect of cyst fluid on surrounding ovarian tissue. Women who have undergone surgical treatment of endometriomas — particularly repeated surgeries — may have further reduced their ovarian reserve as a consequence of the surgery itself, since every excision of an endometrioma removes some normal ovarian tissue along with the cyst wall.
The balance between the damage caused by the endometrioma and the damage caused by surgery to remove it is one of the most clinically challenging decisions in the management of endometriosis for fertility — and it is addressed specifically later in this article.
What Does the Evidence Say About IVF Outcomes in Endometriosis?
The question of whether endometriosis reduces IVF success rates has been studied extensively, and the evidence is nuanced.
In women with mild endometriosis (stages one and two): Multiple studies have found that IVF outcomes in women with mild endometriosis are comparable to those in women with other infertility diagnoses, including unexplained infertility. When egg quality is not severely impaired and ovarian reserve is adequate, IVF in mild endometriosis produces live birth rates that reflect the woman's age and reserve rather than the endometriosis diagnosis specifically.
In women with moderate to severe endometriosis (stages three and four): The evidence consistently shows reduced IVF success rates compared to women without endometriosis — primarily attributable to the egg quality impairment and ovarian reserve reduction associated with more extensive disease. Studies report lower numbers of eggs retrieved, lower fertilization rates, and lower blastocyst development rates in women with severe endometriosis compared to age-matched controls.
However — and this is clinically important — the reduction in success rates is not absolute, and many women with moderate to severe endometriosis achieve pregnancy through IVF. The reduction in success rates means that more cycles may be required to achieve cumulative success, and that realistic expectations must reflect the specific ovarian reserve and egg quality of the individual patient.
After surgical treatment of endometriomas: The evidence on whether surgical removal of endometriomas before IVF improves or worsens outcomes is complex and has shifted significantly in recent years. Older guidance recommended routine surgical excision of endometriomas before IVF. Current evidence is more nuanced — recognizing that surgery damages the surrounding normal ovarian tissue and can reduce ovarian reserve, potentially leaving the patient with fewer eggs per stimulation cycle after surgery than before it.
The current approach at Metro IVF — consistent with the most current evidence-based guidance — is individualized. Surgery for endometriomas before IVF is considered when the endometrioma is large (typically above 3 to 4 cm), when it is causing pain that requires treatment independent of fertility considerations, when the endometrioma is preventing adequate access to follicles at retrieval, when there is diagnostic uncertainty about the nature of the cyst, or when the patient has failed IVF cycles and the endometrioma may be contributing to poor outcomes. In women with small endometriomas and adequate ovarian reserve, proceeding with IVF without surgery — monitoring the cyst but not operating — is often the most appropriate approach, preserving the ovarian reserve for the stimulation cycle.
Managing Endometriosis in an IVF Cycle: The Protocol Considerations
When a woman with endometriosis undergoes IVF at Metro IVF, the stimulation protocol is designed with specific attention to the particular challenges that endometriosis creates.
Stimulation approach. For women with endometriosis-related reduced ovarian reserve, the stimulation protocol is calibrated to the available follicular pool — typically using a moderate dose with careful monitoring to maximize the quality of the limited eggs available without stressing the remaining reserve. For women whose endometriosis has not significantly reduced their reserve, a standard protocol appropriate for their age and AMH is used.
Pre-treatment with GnRH agonist. There is evidence that a period of pituitary suppression with a GnRH agonist — typically given for two to three months before the IVF stimulation cycle begins — may improve IVF outcomes in women with endometriosis. The proposed mechanism involves reduction of the peritoneal inflammatory environment and suppression of endometriotic activity before stimulation begins. This approach is considered at Metro IVF in appropriate patients — particularly those with known stage three or four endometriosis — on an individualized basis, with the recognition that the evidence is supportive but not conclusive.
Antioxidant pre-treatment. Given the oxidative stress environment created by endometriosis, antioxidant supplementation — CoQ10, vitamin C, vitamin E — in the months before IVF may partially mitigate the oxidative damage to developing follicles. This is part of the pre-cycle preparation for women with endometriosis at Metro IVF.
Freeze-all strategy. For women with endometriosis, a freeze-all strategy — freezing all embryos from the stimulation cycle and performing a frozen embryo transfer in a subsequent cycle — may be preferable to fresh transfer. The rationale is that the peritoneal environment during an active stimulation cycle may be less optimal for implantation than a subsequent cycle in which the ovaries have returned to baseline. Evidence supporting this approach specifically in endometriosis patients is accumulating.
Careful aspiration of endometriomas. During egg retrieval in women with ovarian endometriomas, the aspiration approach is carefully managed to minimize contamination of retrieved follicular fluid with endometrioma cyst content, which could be damaging to eggs from adjacent follicles.
The Role of Surgical Treatment Before IVF
The decision about whether to treat endometriosis surgically before IVF is one of the most clinically debated areas in the management of this condition, and it deserves a direct and honest discussion.
For women with minimal to mild endometriosis and no endometriomas, laparoscopic surgery before IVF may improve natural conception rates — through the removal of implants and adhesiolysis — but the evidence for improved IVF success specifically is limited. In women who are proceeding directly to IVF rather than attempting natural or IUI-assisted conception, the benefit of surgery for mild endometriosis is not well established.
For women with moderate to severe endometriosis with significant adhesions and anatomical distortion, laparoscopic surgery to restore pelvic anatomy — adhesiolysis, excision of deep implants, restoration of ovarian and tubal mobility — may be beneficial before IVF, particularly if natural conception has been attempted without success or if the anatomical distortion is severe enough to risk complications at egg retrieval.
For women with endometriomas, the decision is as described above — individualized based on cyst size, ovarian reserve, symptoms, and whether the cyst is impeding retrieval access.
At Metro IVF, the surgical decision is made as part of a comprehensive assessment of the individual patient — not as a blanket recommendation applied to all endometriosis patients. Dr. Soni's approach involves discussing the specific clinical picture, the available evidence, and the couple's timeline and priorities before recommending any surgical intervention before IVF.
The Honest Prognosis
The honest clinical prognosis for a woman with endometriosis pursuing IVF at Metro IVF depends on the specific features of her presentation — and it is this individual prognosis, not a generic endometriosis prognosis, that guides the clinical conversation.
A 32-year-old woman with stage two endometriosis, an AMH of 2.0 ng/mL, and no endometriomas has a prognosis that reflects her age and reserve rather than her endometriosis — IVF success rates for her are comparable to those of women without endometriosis at similar reserve levels.
A 36-year-old woman with bilateral endometriomas, an AMH of 0.6 ng/mL as a consequence of the ovarian damage they have caused, and previous unsuccessful IVF cycles at another clinic has a more challenging clinical picture — one that warrants honest discussion of realistic per-cycle success rates, the role of surgery, the protocol optimization available, and the point at which donor egg IVF becomes a more appropriate path than continued autologous attempts.
Between these two presentations lies the majority of endometriosis patients — each with their own specific combination of factors, each requiring an individual assessment rather than a categorical answer to the question of whether endometriosis reduces IVF chances.
Your Next Step
If you have endometriosis and are considering IVF — or have been through IVF with endometriosis and are uncertain whether the protocol was optimally designed for your specific presentation — a consultation with Dr. Ashish Soni at Metro IVF in Ambikapur provides the individualized assessment that this condition demands.
The question "does endometriosis reduce my IVF chances?" has an answer that is specific to you. Finding that answer — and designing a treatment plan that addresses your specific clinical picture — is what the first consultation at Metro IVF makes possible.
Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist
Endometriosis and IVF — the honest answer depends on your specific situation. Book your consultation with Dr. Ashish Soni at Metro IVF today.